TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02924857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chocolate Touch
Description: The Chocolate Touch™ Paclitaxel Coated Balloon Catheter is indicated for balloon dilatation, after appropriate vessel preparation as needed, of lesions in native superficial femoral or popliteal arteries up to 18 cm in length that are appropriate for angioplasty with balloon diameters from 3.5 mm to 6.0mm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lutonix Drug Coated Balloon
Description: The Lutonix® 035 Drug Coated Balloon Catheter is indicated for improving luminal diameter for the treatment of obstructive de novo or non-stented restenotic lesions (≤ 18 cm in length) in native femoropopliteal arteries having reference vessel diameters of 4 mm to 6 mm.
Study: NCT01375881

Intervention type: DRUG
Intervention: darunavir/ritonavir plus background regimen
Description: darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
Study: NCT01584609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penumbra System with Separator 3D
Description: The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Penumbra System alone
Description: The Penumbra System® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.
Study: NCT02993250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-335
Description: Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Odalasvir (ODV)
Description: Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir (SMV)
Description: Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
Study: NCT00187135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLA
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
Study: NCT03706378

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 1
Description: Glucose contains 50g of available carbohydrates

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 2
Description: Glucose contains 50g of available carbohydrates

Intervention type: OTHER
Group type: OTHER
Intervention: Glucose Reference 3
Description: Glucose contains 50g of available carbohydrates
Study: NCT00187135

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: EMLA
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L.M.X4
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L.M.X4
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L.M.X4
Description: All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
Study: NCT03891056

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: metabolic surgery
Description: The study will randomize patients into two arms, one where a laparoscopic gastric bypass will be performed and another that will perform slevee gastrectomy.
Study: NCT03706378

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wheat Yellow Noodle
Description: Wheat Yellow Noodle will contain 50g of available carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beta-glucan yellow Noodle
Description: Beta-glucan yellow noodle will contain 50g of available carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice Roll
Description: Rice Roll will contain 50g of available carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rice Roll with resistant starch
Description: Rice Roll fortified with resistant starch will contain 50g of available carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose Jelly
Description: Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of sucrose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isomaltulose Jelly
Description: Jelly and bread will contain 50g of available carbohydrate. The jelly will contain 25g of Isomaltulose
Study: NCT00919373

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Substrate modification
Description: Catheter Ablation procedure - Substrate modification in sinus rhythm in case of unstable induced monomorphic Ventricular Tachycardia (VT) which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VT ablation
Description: Catheter Ablation of Ventricular Tachycardia (VT) in case of stable VT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICD Implantation
Description: Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ICD Implantation
Description: Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical
Study: NCT00729859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline
Description: Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline + Testosterone gel
Description: Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyline + testosterone gel + anastrozole
Description: Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
Study: NCT03486977

Intervention type: PROCEDURE
Intervention: Evaluation of disease and follow-up
Description: Correspondence medical consultation with specific device

Intervention type: PROCEDURE
Intervention: Evaluation of disease and follow-up
Description: Correspondence medical consultation with specific device
Study: NCT00436358

Intervention type: OTHER
Intervention: Not applicable: none
Description: Please refer to the detailed description section

Intervention type: OTHER
Intervention: Not applicable: none
Description: Please refer to the detailed description section

Intervention type: OTHER
Intervention: Not applicable: none
Description: Please refer to the detailed description section

Intervention type: OTHER
Intervention: Not applicable: none
Description: Please refer to the detailed description section

Intervention type: OTHER
Intervention: Not applicable: none
Description: Please refer to the detailed description section
Study: NCT01161641

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODSH at 0.125 mg/kg/h
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODSH at 0.375 mg/kg/h
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODSH at 0.250 mg/kg/h
Description: ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
Study: NCT03749655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion
Description: The physical activity (PA) promotion intervention will be provided only to the intervention group, and will include: 1) a step-counter with a digital display, 2) an interview discussing motivational issues, favourite daily activities and strategies to become more physically active; and 3) a tailored physical activity coaching plan including an Individualised activity goal (in steps/day) revised twice weekly through consultation sessions (16 sessions in total). Patients' targets will be revised twice weekly during the consultation sessions which will be incorporated into the Pulmonary rehabilitation sessions. The aim is to increase physical activity by 10% each week. The goal can be altered if required.
Study: NCT00246974

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: intravenous
Study: NCT00214786

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Islet cell transplantation
Description: Allogenic islet transplantation
Study: NCT02953444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thirty-Second Mindfulness Practice

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Three-Minute Mindfulness Practice
Study: NCT02942368

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Transcranial direct current stimulation with placement of the anode over the F3 region of the scalp and the cathode over the right supraorbital region.
Study: NCT02737969

Intervention type: DEVICE
Intervention: Transesophageal Echocardiography/angiography (TEE/Angio)
Description: The TEE probe will be inserted into the patient's esophagus, after anesthetic induction or conscious sedation is administered, and removed after the completion of the procedure. Once the TEE probe is placed, the interventional cardiologist will acquire 2 fluoroscopic images with the TEE probe. These images will be used to co-register the ultrasound and fluoroscopy systems. As part of routine care, TEE and fluoroscopy images will be acquired throughout the procedure for clinical purposes. As new fluoroscopy images are acquired, the prototype software will automatically track the location of the TEE probe. When the echocardiographer has an image of a cardiac structure of interest, he may use the prototype software to place landmarks.~The echocardiographer may then press a button to have the landmarks displayed on the fluoroscopy image that is only visible on an assist monitor and will not interfere with the standard fluoroscopy imaging monitor.
Study: NCT01938651

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: diffusion-weighted magnetic resonance imaging
Description: Undergo DW-MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: dynamic contrast-enhanced magnetic resonance imaging
Description: Undergo DCE-MRI
Study: NCT01494844

Intervention type: DEVICE
Group type: OTHER
Intervention: Respiratory monitor patient interface.
Description: Wear each interface for 20 minutes
Study: NCT03205228

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omeprazole
Description: A capsule of Omeprazole 20 mg \& 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: psychoeducation
Description: Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupentixol +Melitracen
Description: A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg \& a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)
Study: NCT00179777

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolysed infant formula
Description: Participants in the Hydrolysed infant formula -group received the test formula, casein hydrolysate (Nutramigen™, Mead Johnson Nutritionals), not containing antigenic CM protein, whenever breast milk is not available.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nonhydrolysed infant formula
Description: Participants in the Nonydrolysed infant formula -group received the CM protein containing control formula which has an addition (20 %) of Nutramigen, whenever breast milk is not available.
Study: NCT03567395

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Melatonin (5 mg sublingual tablet) administered for 3 days
Study: NCT00187135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
Study: NCT03567395

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Honey
Description: Raw Honey (1.5 tablespoons) administered for 3 days
Study: NCT02858999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAD-VCD
Description: 12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles
Study: NCT04673474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022
Description: Participants will receive a single oral dose of Hemay022 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay022
Description: Participants will receive a single oral dose of Hemay022 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
Study: NCT02414360

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortened Format
Description: Shortened format of a systematic review

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full Length
Description: Full length systematic review
Study: NCT00246974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: intravenous
Study: NCT00846001

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass grafting
Description: Standard coronary surgry according guidelines

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting
Description: Standard coronary surgry according guidelines
Study: NCT00187135

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
Study: NCT01682213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Following definitive surgical resection, eligible patients will receive dabrafenib at 150 mg twice a day by mouth for 4 cycles (± 5 days). One cycle is 28 days.
Study: NCT00846001

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epicardial implantation of cardiac resynchronization therapy device
Description: During the cardiac surgery, the CABG+CRT arm patients will be implanted with epicardial leads to the right atrium, right and left ventricles. Left ventricle leads will be fixed to the posterolateral wall provided that there is no scar or fat tissue (behind and 2-3 cm apical than obtuse marginal artery). Right atrial and right ventricular leads will be fixed in a traditional way. Then the leads will be guided into a preformed pocket (left subclavian region) and connected with the CRT device.
Study: NCT01736397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Citrate
Description: Dose depends on serum phosphorus levels collected at each study visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04061512

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone, cyclophosphamide, rituximab
Description: DRC Arm (chemotherapy) consists of dexamethasone, cyclophosphamide and rituximab treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, ibrutinib
Description: RI Arm (chemotherapy free) consists of rituximab and ibrutinib treatment
Study: NCT00246974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: oral
Study: NCT02353065

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging
Description: Point of care ultrasound of fracture site during and post-reduction

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Bedside x-ray
Description: Portable x-ray of fracture post-reduction
Study: NCT04352413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLM60
Description: Administration: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLM60
Description: Administration: Intravenous infusion
Study: NCT01025856

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rich in MUFA diet -PA
Description: The patients will follow a rich in MUFA diet without a physical activity program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: high fiber/low glycemic index diet + pa
Description: patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rich in MUFA diet+PA
Description: Patients will follow for two months a rich in MUFA diet with a physical activity program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High fibre/low glycemic index diet-PA
Description: Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
Study: NCT01142037

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cooked parsnips with parsley
Description: Beginning on Day 9 participants will be given cooked parsnips with parsley at a dose of 2 grams total apiaceous vegetable/kilogram body weight for period 1, and 4 gram/kilogram body weight for period 2.
Study: NCT02240758

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)
Description: The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
Study: NCT00957268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study: NCT03820154

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test
Description: Skin Prick Testing with inhalant allergens
Study: NCT00957268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets
Study: NCT03820154

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Skin Prick Test TAPE
Description: Skin Prick Testing with a Tape, integrating the allergens and needles
Study: NCT03364374

Intervention type: BEHAVIORAL
Intervention: Postural counseling
Description: A therapist will provide verbal/physical cues to improve the participants posture

Intervention type: BEHAVIORAL
Intervention: Postural counseling
Description: A therapist will provide verbal/physical cues to improve the participants posture
Study: NCT03635047

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AL002
Description: Single-doses of AL002 in up to 9 dose-escalating cohorts
Study: NCT02965820

Intervention type: DEVICE
Group type: OTHER
Intervention: Opti-Free® PureMoist® contact lens solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Opti-Free® PureMoist® contact lens solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Multi-Purpose Contact Lens Solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Habitual Multi-Purpose Contact Lens Solution